Niraparib Approved for Frontline Maintenance: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

The FDA has now expanded the approval of niraparib (Zejula®, GlaxoSmithKline) to include maintenance therapy for adults with metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. This frontline maintenance approval adds to previous approvals for third-line or later maintenance therapy in these cancers regardless of HRD...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.